Collectively, these findings highlight the unique therapeutic vulnerabilities of TP53/RB1 co‐altered tumors and suggest that targeting cell cycle and PI3K/mTOR signaling pathways may represent effective treatment strategies in this high‐risk cancer subgroup. This evidence concerns the gene TP53 and cancer.